Robert Duggan Buys Shares of Summit Therapeutics Inc. $SMMT
Key Points
- Robert Duggan bought 3,810,000 shares of Summit Therapeutics Inc. ($SMMT) worth $49.99 million.
- $SMMT last traded around $14.01.
Robert Duggan, Co-Chief Executive Officer at Summit Therapeutics Inc. ($SMMT), bought 3,810,000 shares at an average price of $13.12, for a total transaction of $49.99 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Summit Therapeutics Inc. ($SMMT) Stock
Summit Therapeutics Inc. Earnings
Analysts Set New Price Targets
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.